Precision Medicine News and Research

RSS

Researchers synthesize molecule to block abnormal protein in cancer cells

In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.

27 Sep 2010

New analytical technique to improve personalized medicine

In the future, even before the start of the treatment, physicians will be able to establish how patient's blood binds a given medicine and what doze should be applied in order to obtain the concentration in the body that would be optimal for the treatment. A new simple method of analysis of chemical reactions proceeding in solutions has been developed in the Institute of Physical Chemistry of the Polish Academy of Sciences.

23 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Ninth Annual World Conference of the Human Proteome Organization -- Agilent Technologies Inc. (NYSE:A) today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

22 Sep 2010

Hastings Center Report examines ethical controversies over use of personalized medicine

As government support for personalized medicine grows, a consumer advocate, a patient, and bioethicists explore ethical controversies. Direct-to-consumer genetic tests, privacy, targeted cancer therapies, and Henrietta Lacks are among topics in a special issue of the Hastings center Report

18 Sep 2010

CINJ, NJDHSS partner to create Center of Excellence for Cancer Surveillance

A new partnership between The Cancer Institute of New Jersey, the state's only National Cancer Institute -designated Comprehensive Cancer Center, and the New Jersey Department of Health and Senior Services will create a Center of Excellence for Cancer Surveillance to help track, examine, prevent and control cancer. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.

18 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors

20/20 GeneSystems, Inc. announced today at ADAPT 2010, an industry meeting focusing on advancing personalized medicine, the commercial launch of their patented technology for biomarker identification in tumors and other tissue samples. 20/20 is currently offering the technology to industry and academic researchers under service contracts.

15 Sep 2010

Genomas awarded method patent for PhyzioGenomics Technology

Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

13 Sep 2010

LabCorp acquires Genzyme Genetics for $925 million

Laboratory Corporation of America Holdings, today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.

13 Sep 2010

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

The College of American Pathologists (CAP) recently signed Memoranda of Understanding (MOUs) with the Canadian Association of Pathologists (CAP-ACP) and the Royal College of Pathologists Australasia (RCPA), forging a collaboration in the development of cancer datasets, also called protocols. The CAP Cancer Protocols are designed as a guideline for definitive cancer reporting.

13 Sep 2010

Research into role of genetic variation in drug-induced hypersensitivity reactions

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.

10 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

Scientists gather to present research findings at ASHG 2010 Meeting

The world's top scientists and clinicians in the human genetics field will gather in Washington, D.C., to present their latest research findings at the 60th Annual Meeting of the American Society of Human Genetics, from Tuesday, November 2, through Saturday, November 6, 2010, at the Walter E. Washington Convention Center in D.C.

8 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers' genetic make-up influences their quitting success.

8 Sep 2010

Stratos Genomics closes Series-A financing deal

Stratos Genomics Inc. today announced it has closed a Series-A financing deal of $4 million to continue development of its ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics. The round was led by Fisk Ventures and included Stratos Group LLC.

8 Sep 2010

UCSF scientists to receive two grants for personalized medicine research

UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual's response to medication and to strengthen a global network of researchers involved in these efforts.

7 Sep 2010

ECRI Institute's 17th Annual Conference to be held October 19-20, at NIH

With the advent of healthcare reform, the United States is embarking on an unprecedented effort to determine which health care intervention works best for the diagnosis or treatment of a given disease or condition. While comparative effectiveness and personalized medicine evolved separately, these significant trends interface, increasingly, in the healthcare systems.

3 Sep 2010

Precision Medicine News and Research

Researchers synthesize molecule to block abnormal protein in cancer cells

New analytical technique to improve personalized medicine

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Hastings Center Report examines ethical controversies over use of personalized medicine

CINJ, NJDHSS partner to create Center of Excellence for Cancer Surveillance

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors

Genomas awarded method patent for PhyzioGenomics Technology

LabCorp acquires Genzyme Genetics for $925 million

CAP forges collaboration with CAP-ACP and RCPA for development of cancer protocols

Research into role of genetic variation in drug-induced hypersensitivity reactions

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

Scientists gather to present research findings at ASHG 2010 Meeting

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

Penn receives $12M NIH grant to study pharmacogenetics of nicotine addiction treatment

Stratos Genomics closes Series-A financing deal

UCSF scientists to receive two grants for personalized medicine research

ECRI Institute's 17th Annual Conference to be held October 19-20, at NIH

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News